Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
Institut Curie · Mount Vernon Cancer Centre · +8 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
651
total citations
- FWCI
- 23.70
- Percentile
- 100%
- References
- 18
Citations per year
Authors
12Topics & keywords
Topics
Keywords
- Medicine
- Lapatinib
- Capecitabine
- Trastuzumab emtansine
- Taxane
- Trastuzumab
- Internal medicine
- Oncology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.